CureVac(CVAC) - 2021 Q2 - Quarterly Report

Exhibit 99.1 CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60 · Unique pivotal study conducted in 10 countries in fast changing variant environment; 15 COVID-19 variant strains present for ef icacy analysis; original strain almost completely absent · Statistical success criteria for primary endpoint met on basis of 228 adjudicated cases · Vaccine ef icacy of 48% against COVID-19 of any severity across all age gr ...